Further developments in the quantification of small RNA viruses by U.V. photometry of sucrose density gradients.

PubWeight™: 0.81‹?›

🔗 View Article (PMID 6281106)

Published in Dev Biol Stand on January 01, 1981

Authors

T R Doel, B W Fletton, R F Staple

Articles by these authors

A re-appraisal of the biochemical map of foot-and-mouth disease virus RNA. J Gen Virol (1978) 2.06

Purification and identification of the RNA-dependent RNA polymerase of foot-and-mouth disease virus. J Gen Virol (1979) 1.50

A T cell epitope in VP1 of foot-and-mouth disease virus is immunodominant for vaccinated cattle. J Immunol (1991) 1.31

Foot-and-mouth disease: the risk for Great Britain after 1992. Vet Rec (1992) 1.25

Tryptic peptide analysis of the structural proteins of vesicular stomatitis virus. J Gen Virol (1978) 1.24

A model for vesicular exanthema virus, the prototype of the calicivirus group. J Gen Virol (1978) 1.22

Thermal stability of foot-and-mouth disease virus. Arch Virol (1981) 1.22

Isotype responses of infected, virus-vaccinated and peptide-vaccinated cattle to foot-and-mouth disease virus. Vaccine (1990) 1.19

Moleculas aspects of the antigenic variation of swine vesicular disease and Coxsackie B5 viruses. J Gen Virol (1977) 1.10

Preliminary studies on the development of a swine vesicular disease vaccine. Arch Gesamte Virusforsch (1974) 1.05

T cell-dependent induction of antibody against foot-and-mouth disease virus in a mouse model. J Gen Virol (1989) 1.01

High-affinity antibody induced by immunization with a synthetic peptide is associated with protection of cattle against foot-and-mouth disease. Immunology (1991) 0.99

International bank for foot-and-mouth disease vaccine: assessment of Montanide ISA 25 and ISA 206, two commercially available oil adjuvants. Vaccine (1996) 0.98

The growth of a virulent strain of African swine fever virus in domestic pigs. J Hyg (Lond) (1968) 0.96

Heterotypic recognition of foot-and-mouth disease virus by cattle lymphocytes. J Gen Virol (1990) 0.95

Heterotypic recognition of recombinant FMDV proteins by bovine T-cells: the polymerase (P3Dpol) as an immunodominant T-cell immunogen. Virus Res (1998) 0.95

MHC class II restricted recognition of FMDV peptides by bovine T cells. Immunology (1991) 0.94

Detection of foot-and-mouth disease viral sequences in clinical specimens and ethyleneimine-inactivated preparations by the polymerase chain reaction. Vaccine (1993) 0.93

Studies on the pathogenesis of rinderpest in experimental cattle. IV. Proliferation of the virus following contact infection. J Hyg (Lond) (1965) 0.92

The expression of the proteins of equine herpesvirus 1 which share homology with herpes simplex virus 1 glycoproteins H and L. Virus Res (1996) 0.91

Biochemical aspects of variation in foot-and-mouth disease virus. J Gen Virol (1980) 0.91

Comparative immunogenicity of 146S, 75S and 12S particles of foot-and-mouth disease virus. Arch Virol (1982) 0.87

Mouse protection test as a predictor of the protective capacity of synthetic foot-and-mouth disease vaccines. Vaccine (1991) 0.85

Synthetic peptide vaccines against foot-and-mouth disease. I. Duration of the immune response and priming in guinea-pigs, rabbits and mice. J Biol Stand (1987) 0.83

An international collaborative study on foot and mouth disease virus assay methods. 2. Quantification of 146S particles. J Biol Stand (1985) 0.82

The effect of acetylethyleneimine upon a strain of inactivated foot-and-mouth disease virus stored at 4 degrees C. Arch Virol (1975) 0.81

Studies on glycoprotein 13 (gp13) of equid herpesvirus 1 using affinity-purified gp13, glycoprotein-specific monoclonal antibodies and synthetic peptides in a hamster model. J Gen Virol (1991) 0.81

Synthetic peptide vaccines against foot-and-mouth disease. II. Comparison of the response of guinea-pigs, rabbits and mice to various formulations. J Biol Stand (1987) 0.80

Maturation of functional antibody affinity in animals immunised with synthetic foot-and-mouth disease virus. Res Vet Sci (1992) 0.79

The elution of foot-and-mouth disease virus from vaccines adjuvanted with aluminium hydroxide and with saponin. J Biol Stand (1982) 0.78

Prospects for improved foot and mouth disease vaccines. Vaccine (1985) 0.78

A protective anti-peptide antibody against the immunodominant site of the A24 Cruzeiro strain of foot-and-mouth disease virus and its reactivity with other subtype viruses containing the same minimum binding sequence. J Gen Virol (1996) 0.77

Cross-reactive and serotype-specific antibodies against foot-and-mouth disease virus generated by different regions of the same synthetic peptide. J Virol (1992) 0.77

Induction of antibody to foot-and-mouth disease virus in presensitized mouse spleen cell cultures. J Virol (1984) 0.75

Interactions between saponin and 146S particles of foot-and-mouth disease virus. J Biol Stand (1982) 0.75

Observations and implications of proteolysis in preparations of foot-and-mouth disease virus. Dev Biol Stand (1981) 0.75

The detection and inhibition of proteolytic enzyme activity in concentrated preparations of inactivated foot-and-mouth disease virus. J Biol Stand (1983) 0.75

Isolation of capsid proteins of foot-and-mouth disease virus by chromatofocusing. J Virol Methods (1983) 0.75

The production and use of swine vesicular disease virus from pig kidney monolayer cells grown on the surface of 3-mm-diameter glass spheres. Biotechnol Bioeng (1982) 0.75

The stability and potency of vaccines prepared from inactivated foot-and-mouth disease virus concentrates. J Biol Stand (1984) 0.75

[Effects of temperature and inactivators on strains of foot-and-mouth disease virus in Colombia]. Rev Latinoam Microbiol (1984) 0.75

Removal of acetylethyleneimine from suspensions of inactivated foot-and-mouth disease virus. Lab Pract (1975) 0.75

A comparative study of the surface projections of different strains of vesicular stomatitis virus. J Gen Virol (1975) 0.75

Qualitative assessment of 146 S particles of foot-and-mouth disease virus in preparations destined for vaccines. J Biol Stand (1982) 0.75

The evaluation of a physical method for the quantification of inactivated poliovirus particles and its relationship to D-antigenicity and potency testing in rats. J Biol Stand (1984) 0.75